Sartorius completes acquisition of MatTek
|
EQS-News: SARTORIUS AG
/ Key word(s): Mergers & Acquisitions
Göttingen, Germany | July 1, 2025
Sartorius completes acquisition of MatTek The life science group Sartorius has successfully closed the acquisition of MatTek Corp, including Visikol Inc, from the Swedish BICO Group AB, as announced in April. The acquisition was completed on July 1, 2025, following the receipt of the required regulatory approval and the fulfillment of other customary closing conditions. With the integration of the business into its Lab Products and Services division, Sartorius is expanding its cell technology portfolio and creating synergies with existing solutions for drug development, including cell analysis instruments, reagents, and AI models. MatTek is a leading developer and manufacturer of human cell-based microtissues and 3D models that accelerate drug development. The advanced cell models mimic the structure and function of human tissue and deliver more accurate, cost-effective, and reproducible results compared to traditional 2D cell cultures, while reducing the need for animal testing. The company employs more than 80 people at its headquarters in Ashland, Massachusetts, USA, and at its production site in Bratislava, Slovakia. A profile of Sartorius Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. Around 13,500 employees are working for customers around the globe. Visit our Newsroom and follow Sartorius on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com Additional features: File: Sartorius completes acquisition of MatTek | Media Release
01.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | SARTORIUS AG |
| Otto-Brenner-Straße 20 | |
| 37079 Göttingen | |
| Germany | |
| Phone: | +49.(0)551-308.0 |
| Fax: | +49.(0)551-308.3289 |
| E-mail: | info@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | DE0007165631, DE0007165607 |
| WKN: | 716563, 716560 |
| Indices: | DAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2162694 |
| End of News | EQS News Service |
|
|
2162694 01.07.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.